WO2002098865A3 - Inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations de ces inhibiteurs - Google Patents

Inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations de ces inhibiteurs Download PDF

Info

Publication number
WO2002098865A3
WO2002098865A3 PCT/FR2002/001952 FR0201952W WO02098865A3 WO 2002098865 A3 WO2002098865 A3 WO 2002098865A3 FR 0201952 W FR0201952 W FR 0201952W WO 02098865 A3 WO02098865 A3 WO 02098865A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
cyclic nucleotide
phosphodiesterase inhibitors
nucleotide phosphodiesterase
novel
Prior art date
Application number
PCT/FR2002/001952
Other languages
English (en)
Other versions
WO2002098865A2 (fr
Inventor
Jean-Jacques Bourguignon
Yan Lagouge
Claire Lugnier
Eveline Klotz
Jean-Paul Macher
Pierre Raboisson
Dominique Schultz
Original Assignee
Neuro3D
Jean-Jacques Bourguignon
Yan Lagouge
Claire Lugnier
Eveline Klotz
Jean-Paul Macher
Pierre Raboisson
Dominique Schultz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuro3D, Jean-Jacques Bourguignon, Yan Lagouge, Claire Lugnier, Eveline Klotz, Jean-Paul Macher, Pierre Raboisson, Dominique Schultz filed Critical Neuro3D
Priority to EP02747514A priority Critical patent/EP1392663A2/fr
Priority to US10/479,000 priority patent/US7250410B2/en
Priority to CA002446696A priority patent/CA2446696A1/fr
Priority to IL15910502A priority patent/IL159105A0/xx
Priority to NZ529582A priority patent/NZ529582A/en
Priority to AU2002317910A priority patent/AU2002317910B2/en
Priority to JP2003501989A priority patent/JP2005503356A/ja
Publication of WO2002098865A2 publication Critical patent/WO2002098865A2/fr
Publication of WO2002098865A3 publication Critical patent/WO2002098865A3/fr
Priority to IL159105A priority patent/IL159105A/en
Priority to AU2008221554A priority patent/AU2008221554A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/02—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

L'invention concerne de nouveaux dérivés de type benzodiazépinones et leurs applications dans le domaine thérapeutique tout particulièrement pour le traitement de pathologies impliquant l'activité d'une phosphodiestérase de nucléotides cycliques. Elle concerne également des procédés pour leur préparation et de nouveaux intermédiaires de synthèse. Les composés de l'invention répondent plus particulièrement à la formule générale (I) :
PCT/FR2002/001952 2001-06-07 2002-06-07 Inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations de ces inhibiteurs WO2002098865A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP02747514A EP1392663A2 (fr) 2001-06-07 2002-06-07 Inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations de ces inhibiteurs
US10/479,000 US7250410B2 (en) 2001-06-07 2002-06-07 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof
CA002446696A CA2446696A1 (fr) 2001-06-07 2002-06-07 Inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations de ces inhibiteurs
IL15910502A IL159105A0 (en) 2001-06-07 2002-06-07 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof
NZ529582A NZ529582A (en) 2001-06-07 2002-06-07 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof
AU2002317910A AU2002317910B2 (en) 2001-06-07 2002-06-07 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof
JP2003501989A JP2005503356A (ja) 2001-06-07 2002-06-07 環状ヌクレオチドホスホジエステラーゼ阻害剤、その製造および使用
IL159105A IL159105A (en) 2001-06-07 2003-11-27 Derivatives of benzo - 1,4 - diazepine, 2 - oxo as inhibitors of ring nucleotide phosphodiesterase, their preparation and use
AU2008221554A AU2008221554A1 (en) 2001-06-07 2008-09-18 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0107458 2001-06-07
FR01/07458 2001-06-07

Publications (2)

Publication Number Publication Date
WO2002098865A2 WO2002098865A2 (fr) 2002-12-12
WO2002098865A3 true WO2002098865A3 (fr) 2003-02-27

Family

ID=8864056

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2002/001952 WO2002098865A2 (fr) 2001-06-07 2002-06-07 Inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations de ces inhibiteurs

Country Status (9)

Country Link
US (1) US7250410B2 (fr)
EP (1) EP1392663A2 (fr)
JP (1) JP2005503356A (fr)
AU (2) AU2002317910B2 (fr)
CA (1) CA2446696A1 (fr)
IL (2) IL159105A0 (fr)
NZ (1) NZ529582A (fr)
WO (1) WO2002098865A2 (fr)
ZA (1) ZA200400057B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9126978B2 (en) 2009-11-17 2015-09-08 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2062583B1 (fr) 1999-04-30 2012-12-26 The Regents of the University of Michigan Applications thérapeutiques de benzodiazépines pro-apoptotiques
US20030119029A1 (en) * 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
US20060025388A1 (en) * 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
US20050113460A1 (en) * 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US7144880B2 (en) * 1999-04-30 2006-12-05 Regents Of The University Of Michigan Compositions relating to novel compounds and targets thereof
CN1703395A (zh) * 2002-08-09 2005-11-30 特兰斯泰克制药公司 芳基和杂芳基化合物以及调节凝血的方法
ES2315546T3 (es) * 2002-10-30 2009-04-01 Via Pharmaceuticals, Inc. Inhibidores delas fosfodiesterasas de los nucleotidos ciclicos, que presentan una estructura de benzodiazepina, y su uso en terapia.
FR2846653B1 (fr) * 2002-10-30 2007-04-20 Neuro3D Inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations
WO2005014532A1 (fr) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Composes aryle et heteroaryle, compositions et procedes associes
US7208601B2 (en) * 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
EP1548011A1 (fr) * 2003-12-23 2005-06-29 Neuro3D Dérivés de 1,4-benzodiazépine-2-one comme inhibiteurs de PDE2 phosphodiesterase, leurs préparation et utilisation thérapeutique
US20050272723A1 (en) * 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US20090275099A1 (en) * 2004-04-27 2009-11-05 Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
FR2870539B1 (fr) * 2004-05-19 2006-08-04 Greenpharma Sa Sa Nouvelles methodes et medicaments
US7572783B2 (en) 2004-08-13 2009-08-11 Amgen Inc. Substituted benzofused heterocycles
US20060052369A1 (en) * 2004-09-07 2006-03-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
WO2007053193A2 (fr) * 2005-06-01 2007-05-10 The Regents Of The University Of Michigan Préparations de benzodiazépine non solvatées et méthodes
US20070105844A1 (en) * 2005-10-26 2007-05-10 Regents Of The University Of Michigan Therapeutic compositions and methods
CA2628193C (fr) 2005-11-01 2012-08-14 The Regents Of The University Of Michigan Nouvelles 1,4-benzodiazepine-2,5-diones dotees de proprietes therapeutiques
US7759338B2 (en) * 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
MX2008015488A (es) 2006-06-09 2009-02-12 Univ Michigan Composiciones y metodos relacionados con compuestos novedosos y objetivos de los mismos.
MX2009009645A (es) 2007-03-09 2009-11-19 Univ Michigan Composiciones y metodos relacionados con nuevos compuestos y objetivos de los mismos.
JP2010526825A (ja) * 2007-05-10 2010-08-05 エーエムアール テクノロジー インコーポレイテッド アリール置換およびヘテロアリール置換テトラヒドロベンゾ−１，４−ジアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用
CA2698248C (fr) * 2007-09-14 2017-08-29 The Regents Of The University Of Michigan Derives acyles phenyles de guanidine comme inhibiteurs de la f1f0-atpase et leur utilisation
WO2009037302A1 (fr) * 2007-09-18 2009-03-26 Via Pharmaceuticals, Inc. 1,4-benzodiazépines 5-substituées en tant qu'inhibiteurs de phosphodiestérase
AU2008323945B2 (en) * 2007-11-06 2013-11-28 The Regents Of The University Of Michigan Benzodiazepinone compounds useful in the treatment of skin conditions
AU2009291632B2 (en) 2008-09-11 2013-04-04 The Regents Of The University Of Michigan Aryl guanidine F1F0-ATPase inhibitors and related methods
US8604023B2 (en) 2009-04-17 2013-12-10 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
WO2011035124A1 (fr) 2009-09-18 2011-03-24 The Regents Of The University Of Michigan Composés de benzodiazépinone et méthodes de traitement les utilisant
WO2011062766A2 (fr) 2009-11-17 2011-05-26 The Regents Of The University Of Michigan 1,4-benzodiazépine-2,5-diones et composés apparentés présentant des propriétés thérapeutiques
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2012075456A1 (fr) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Inhibiteurs de bromodomaines et leurs utilisations
EP2705039B1 (fr) 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Inhibiteurs de bromodomaines et leurs utilisations
WO2012174487A2 (fr) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Inhibiteurs à bromodomaine et leurs utilisations
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
EP2864336B1 (fr) 2012-06-06 2016-11-23 Constellation Pharmaceuticals, Inc. Inhibiteurs de bromo-domaine de benzo[b]isoxazoloazépines et applications associées
ES2725928T3 (es) 2014-06-20 2019-09-30 Constellation Pharmaceuticals Inc Formas cristalinas de 2-((4S)-6-(4-clorofenil)-1-metil-4H-benzo[c]isoxazolo[4,5-e]azepin-4-il)acetamida
WO2023220395A1 (fr) * 2022-05-13 2023-11-16 University Of Cincinnati Analogues de benzodiazépine et méthodes d'utilisation dans le traitement du cancer

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB972963A (en) * 1959-12-10 1964-10-21 Hoffmann La Roche A process for the manufacture of benzodiazepine derivatives
US3182067A (en) * 1964-04-09 1965-05-04 Hoffmann La Roche Benzodiazepine compounds
US3398159A (en) * 1961-06-20 1968-08-20 Hoffmann La Roche Aminophenyl heterocyclic ketones
FR7666M (fr) * 1967-06-23 1970-02-09
DE2017060A1 (de) * 1969-04-18 1970-10-29 Sumitomo Chemical Company Ltd., Osaka (Japan) Verfahren zur Herstellung von Benzodiazepinen und ihren Säureadditionssalzen
US3631029A (en) * 1967-12-01 1971-12-28 Sumitomo Chemical Co Process for producing benzodiazepine derivatives
FR2085645A1 (en) * 1970-04-22 1971-12-31 Chimidrog 1-phenyl-2,3-benzodiazepin-4-ones - as tranquillizers
FR2273547A1 (fr) * 1973-01-15 1976-01-02 Hoffmann La Roche Derives de benzodiazepine
DE1795832A1 (de) * 1964-06-15 1976-04-22 Clin Midy O-aminoarylketimine und verfahren zu ihrer herstellung
EP0387618A1 (fr) * 1989-03-08 1990-09-19 Kali-Chemie Pharma GmbH N-(1,4-benzodiazépin-3-yl)amides 1H-indole-2-carboxyliques 1,7-pontés
EP0552665A1 (fr) * 1992-01-24 1993-07-28 F. Hoffmann-La Roche Ag Pyrrolylbenzodiazepinones et médicaments les contenant
WO1997028135A1 (fr) * 1996-02-01 1997-08-07 Schering Aktiengesellschaft Derives de 2,3-benzodiazepine et leur utilisation comme inhibiteurs de recepteurs d'ampa
WO1997034878A1 (fr) * 1996-03-21 1997-09-25 Cocensys, Inc. 2,3-benzodiazepine-4-ones a substitution et leur utilisation
WO2000079263A2 (fr) * 1999-06-18 2000-12-28 Synt:Em S.A. Identification de molecules actives au moyen de parametres physico-chimiques
WO2002051838A1 (fr) * 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Nouvelles benzazepines et derives heterocycliques associes, utilises comme antagonistes du recepteur de l'orexine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3119874A1 (de) 1981-05-19 1982-12-09 Dr. Karl Thomae Gmbh, 7950 Biberach "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB972963A (en) * 1959-12-10 1964-10-21 Hoffmann La Roche A process for the manufacture of benzodiazepine derivatives
US3398159A (en) * 1961-06-20 1968-08-20 Hoffmann La Roche Aminophenyl heterocyclic ketones
US3182067A (en) * 1964-04-09 1965-05-04 Hoffmann La Roche Benzodiazepine compounds
DE1795832A1 (de) * 1964-06-15 1976-04-22 Clin Midy O-aminoarylketimine und verfahren zu ihrer herstellung
FR7666M (fr) * 1967-06-23 1970-02-09
US3631029A (en) * 1967-12-01 1971-12-28 Sumitomo Chemical Co Process for producing benzodiazepine derivatives
DE2017060A1 (de) * 1969-04-18 1970-10-29 Sumitomo Chemical Company Ltd., Osaka (Japan) Verfahren zur Herstellung von Benzodiazepinen und ihren Säureadditionssalzen
FR2085645A1 (en) * 1970-04-22 1971-12-31 Chimidrog 1-phenyl-2,3-benzodiazepin-4-ones - as tranquillizers
FR2273547A1 (fr) * 1973-01-15 1976-01-02 Hoffmann La Roche Derives de benzodiazepine
EP0387618A1 (fr) * 1989-03-08 1990-09-19 Kali-Chemie Pharma GmbH N-(1,4-benzodiazépin-3-yl)amides 1H-indole-2-carboxyliques 1,7-pontés
EP0552665A1 (fr) * 1992-01-24 1993-07-28 F. Hoffmann-La Roche Ag Pyrrolylbenzodiazepinones et médicaments les contenant
WO1997028135A1 (fr) * 1996-02-01 1997-08-07 Schering Aktiengesellschaft Derives de 2,3-benzodiazepine et leur utilisation comme inhibiteurs de recepteurs d'ampa
WO1997034878A1 (fr) * 1996-03-21 1997-09-25 Cocensys, Inc. 2,3-benzodiazepine-4-ones a substitution et leur utilisation
WO2000079263A2 (fr) * 1999-06-18 2000-12-28 Synt:Em S.A. Identification de molecules actives au moyen de parametres physico-chimiques
WO2002051838A1 (fr) * 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Nouvelles benzazepines et derives heterocycliques associes, utilises comme antagonistes du recepteur de l'orexine

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
"AsInEx Compound Collection", 10 May 2001, ASINEX, 6 SHUKINSKAYA STREET, MOSCOW, 123182, RUSSIA *
ANGELA DE SARRO ET AL: "Synthesis and anticonculsant activity of new 2,3-benzobiazepines as AMPA receptor antagonists", FARMACO, SOCIETA CHIMICA ITALIANA, PAVIA, IT, vol. 54, no. 3, 1999, pages 178 - 187, XP002902063, ISSN: 0014-827X *
ANTI-CANCER DRUG DESIGN (2001), 16(1), 7-17 *
C. R. SEANCES ACAD. SCI., SER. C (1980), 290(17), 349-51 *
CHIMIRRI, ALBA ET AL: "1-Aryl-3,5-dihydro-4H-2,3-benzodiazepin-4-ones: Novel AMPA Receptor Antagonists", J. MED. CHEM. (1997), 40(8), 1258-1269, XP002191651 *
CHIMIRRI, ALBA ET AL: "3,5-Dihydro-4H-2,3-benzodiazepine-4-thiones: A New Class of AMPA Receptor Antagonists", J. MED. CHEM. (1998), 41(18), 3409-3416, XP002191652 *
COMBS, DONALD W. ET AL: "Phosphoryl chloride-induced ring contraction of 1,4- benzodiazepinones to (chloromethyl)quinazolines", JOURNAL OF HETEROCYCLIC CHEMISTRY (1986), 23(4), 1263-4, XP002220605 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; BOGATSKII, A. V. ET AL: "Predicting the pharmacological activities of tranquilizers which are 1,4-diazepin-2-one derivatives", XP002220607, retrieved from STN Database accession no. 95:180658 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; BOGZA, S. L. ET AL: "Synthesis of benzo[c]pyrylium salts from 2-(3,4- dimethoxyphenyl)succinic acid derivatives and their transformations", XP002213385, retrieved from STN Database accession no. 126:7948 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; FLAMMANG, MICHEL ET AL: "2,3-Benzodiazepine systems. II. 4-Oxo-3,5-dihydro(4H)-2,3- benzodiazepines. Synthesis and pharmacological study", XP002191654, retrieved from STN Database accession no. 85:46605 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; FLAMMANG, MICHEL: "2,3-Benzodiazepines: 2-amino-3-isoquinolinones from ring contraction of 4-oxo-2,3-benzodiazepines", XP002213384, retrieved from STN Database accession no. 93:167330 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; IVANOV, CH.: "1,4-Benzodiazepines. V. Synthesis of 7,8-dimethoxy-5-[6',7'- dimethoxyisoquinolyl]-1,3-dihydro-2H-1,4-benzodiazepin-2-ones", XP002220608, retrieved from STN Database accession no. 86:189880 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; VASSILEV, LYUBOMIR T. ET AL: "Cell-based screening approach for antitumor drug leads which exploits sensitivity differences between normal and cancer cells: identification of two novel cell-cycle inhibitors", XP002220606, retrieved from STN Database accession no. 136:226419 *
DATABASE CHEMCATS [online] CHEMICAL ABSTRACT SERVICE, COLUMBUS, OHIO, US; XP002213386, retrieved from STN *
EUR. J. MED. CHEM. - CHIM. THER. (1976), 11(1), 83-7 *
GATTA F ET AL: "DERIVATIVES OF 2,3-BENZODIAZEPINE", IL FARMACO, ROME, IT, vol. 40, no. 12, 1985, pages 942 - 955, XP002949896 *
KHIM.-FARM. ZH. (1977), 11(2), 32-6 *
NAGARAJAN, K. ET AL: "Derivatives of 3,5-dihydro-4H-benzo[2,3]diazepin-4-one", J. MED. CHEM. (1972), 15(10), 1091-2, XP002191650 *
SHIMAMOTO K ET AL: "PHARMACOLOGICAL SCREENING OF NEW BANZODIAZEPINES IN MICE", TAKEDA KENKYUSHO HO - JOURNAL OF THE TAKEDA RESEARCH LABORATORIES, OSAKA, JP, vol. 29, no. 1, 1970, pages 134 - 144, XP000965475, ISSN: 0371-5167 *
SOTIRIADIS, A. ET AL: "New synthesis of substituted 3,5-dihydro-4H-2,3-benzodiazepin-4-ones", J. HETEROCYCL. CHEM. (1974), 11(3), 401-3, XP002213383 *
SUGASAWA ET AL: "1-Azacycloalkyl-1,4-benzodiazepin-2-ones with antianxiety- antidepressant actions", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 28, no. 6, 1985, pages 699 - 707, XP002159556, ISSN: 0022-2623 *
USP. KVANTOVOI KHIM. KVANTOVOI BIOL., TR. MEZHDUNAR. KONF. (1980), MEETING DATE 1978, VOLUME 2, 33-40. EDITOR(S): PETROV, E. G.;LOEWDIN, PER OLOV; ZENER, M. PUBLISHER: IZD. NAUKOVA DUMKA, KIEV, USSR. *
ZHURNAL ORGANICHESKOI KHIMII (1996), 32(4), 596-603 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9126978B2 (en) 2009-11-17 2015-09-08 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties

Also Published As

Publication number Publication date
AU2008221554A1 (en) 2008-10-09
US20040152888A1 (en) 2004-08-05
CA2446696A1 (fr) 2002-12-12
NZ529582A (en) 2006-10-27
AU2002317910B2 (en) 2008-06-19
US7250410B2 (en) 2007-07-31
JP2005503356A (ja) 2005-02-03
ZA200400057B (en) 2005-02-21
IL159105A0 (en) 2004-05-12
IL159105A (en) 2009-05-04
EP1392663A2 (fr) 2004-03-03
WO2002098865A2 (fr) 2002-12-12

Similar Documents

Publication Publication Date Title
WO2002098865A3 (fr) Inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations de ces inhibiteurs
WO2004041258A8 (fr) Utilisation d’inhibiteurs des phosphodiesterases des nucleotides cycliques, ayant une structure benzodiazepinique en therapie
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
MY133392A (en) Novel substituted pyrazole derivatives
HK1053122A1 (en) Pyrimidine compounds and their use in the preparation of a triazolo-pyrimidine carba nucleoside
WO2002102313A3 (fr) Inhibiteurs pyrimidine de la phosphodiesterase (pde) 7
MY138478A (en) Benzazepine derivatives for the treatment of neurological disorders
MY132106A (en) New pyridazin-3(2h)-one derivatives
WO2005021536A3 (fr) Nouveaux composes
TW200503710A (en) Novel compounds
IL172015A (en) Phosphonate grouping shaft compounds, method of preparation and use thereof for the preparation of drugs for the treatment of viral infection
MXPA05010440A (es) Amidas del acido isoquinolina-5-sulfonico como inhibidores de la akt (proteina quinasa b).
WO2004096233A3 (fr) Analogues d'un phosphonate nucleosidique
PL371127A1 (en) 6-aminomorphinane derivatives, method for the production and use thereof
IL150061A0 (en) Purine derivatives
IL166057A0 (en) Urea-substituted and urethane-substituted acylureas methods for the production thereof and their useas medicaments
AU2003293042A8 (en) Process for purification of plasmid dna
MXPA04004621A (es) Nucleotidos, preparaciones de los mismos y su utilizacion como inhibidores de polimerasas virales de arn.
WO2000064424A8 (fr) Medicaments destines au traitement de la mucoviscidose
UA83821C2 (ru) Производные бензолсульфонамидов, способ их получения и их применение для лечения воспалительных заболеваний и утоления боли
WO2004026814A3 (fr) Procede de synthese d'intermediaires utiles dans la synthese d'inhibiteurs de tubuline
HK1078781A1 (en) Processes for preparing 1,3-dioxolane nucleosides
PL359409A1 (en) Compounds useful for the preparation of medicaments with phosphodiesterase iv inhibitory activity
MXPA04005151A (es) Compuestos terapeuticos.
WO2003076426A3 (fr) Composes therapeutiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1028/MUMNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2446696

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 529582

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002747514

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10479000

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 159105

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002317910

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003501989

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004/00057

Country of ref document: ZA

Ref document number: 200400057

Country of ref document: ZA

WWP Wipo information: published in national office

Ref document number: 2002747514

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 194253

Country of ref document: IL